phospho-IRS1 (Ser307)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 2736R
英文名称phospho-IRS1 (Ser307)
中文名称磷酸化胰岛素受体底物p-IRS-1/2抗体
别 名IRS1 (phospho S307); p-IRS-1; IRS1(phospho-Ser307); HIRS 1; HIRS1; Insulin Receptor Substrate 1; IRS-1; IRS 1; IRS1; OTTHUMP00000164234; IRS1_HUMAN.
JournalPMIDIFApplicationInternational Immunopharmacology (2015)262631682.4720WB
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 细胞生物 **学 神经生物学 糖尿病 细胞膜蛋白
抗体来源Rabbit
克隆类型Polyclonal
phospho-IRS1 (Ser307)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=1μg /test IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量132kDa
细胞定位细胞膜
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human IRS1 around the phosphorylation site of Ser307 [TE(p-S)IT]:251-350/1242
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-IRS1 (Ser307)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
Insulin receptor substrates (IRS) are responsible for several insulin related activities, such as glucose homeostasis, cell growth, cell transformation, apoptosis and insulin signal transduction. Serine/threonine phosphorylation of IRS1 has been demonstrated to be a negative regulator of insulin signaling and is responsible for its degradation, although IRS1 degradation pathways are not well understood. IRS1 has also been shown to be constitutively activated in cancers such as breast cancer, Wilm's tumors, and adrenal cortical carcinomas, thus making IRS1 phosphorylation and subsequent degradation an attractive therapeutic target. To date there have been four subtypes identified: IRS1, 2, 3 and 4, with IRS1 being widely expressed.
Function:
May mediate the control of various cellular processes by insulin. When phosphorylated by the insulin receptor binds specifically to various cellular proteins containing SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2. Activates phosphatidylinositol 3-kinase when bound to the regulatory p85 subunit.
Subunit:
Interacts with UBTF and PIK3CA. Interacts (via phosphorylated YXXM motifs) with PIK3R1. Interacts with ROCK1 and FER. Interacts (via PH domain) with PHIP. Interacts with GRB2. Interacts with SOCS7. Interacts (via IRS-type PTB domain) with IGF1R and INSR (via the tyrosine-phosphorylated NPXY motif). Interacts with ALK.
Subcellular Location:
Membrane; Single-pass type I membrane protein.
Tissue Specificity:
Isoform Long and isoform Short are predominantly expressed in tissue targets of insulin metabolic effects: liver, adipose tissue and skeletal muscle but are also expressed in the peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta vascular endothelium, fibroblasts, monocytes, granulocytes, erythrocytes and skin. Isoform Short is preferentially expressed in fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Overexpressed in several tumors, including breast, colon, lung, ovary, and thyroid carcinomas.
Post-translational modifications:
Serine phosphorylation of IRS1 is a mechanism for insulin resistance. Ser-312 phosphorylation inhibits insulin action through disruption of IRS1 interaction with the insulin receptor.
Phosphorylation of Tyr-896 is required for GRB2-binding. Phosphorylated by ALK. Phosphorylated at Ser-270, Ser-307, Ser-636 and Ser-1101 by RPS6KB1; phosphorylation induces accelerated degradation of IRS1.
DISEASE:
Polymorphisms in IRS1 may be involved in the etiology of non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853].
Similarity:
Contains 1 IRS-type PTB domain.
Contains 1 PH domain.
SWISS:
P35568
Gene ID:
3667
phospho-IRS1 (Ser307)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-IRS1 (Ser307)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 DDX42 ATP依赖RNA解旋酶DDX42抗体
合格 DDX6 ATP依赖RNA解旋酶DDX6抗体
合格 合格 DEF8 DEF8蛋白抗体
合格 DEFB108B 防御素β-108B/β-defensin 108B抗体
合格 DEFB109 防御素β-109/β-defensin 109抗体
合格 DEFB110 防御素β-110/β-defensin 110抗体
合格 DEFB112 防御素β-112/β-defensin 112抗体
合格 DEFB118 防御素β-118/β-defensin 118抗体
合格 合格 EPOR 红细胞生成素受体抗体
合格 DEFB135 防御素β-135/β-defensin 135抗体
合格 DEGS2 退行性精母细胞同源物2抗体
合格 phospho-delta 1 Catenin (Tyr280) 磷酸化δ连环蛋白抗体
合格 delta Sarcoglycan 肌营养蛋白δ/δ-sarcoglycan抗体
合格 DENN 死亡结构域接头蛋白DENN抗体
合格 DENND1A DENND1A蛋白抗体
合格 RPS6KB1 核糖体S6蛋白激酶抗体
合格 合格 Density Regulated Protein 密度调节蛋白抗体
合格 合格 DEPDC1B/BRCC3 乳腺癌细胞3抗体
合格 DEXI 地塞米松诱导蛋白DEXI抗体
合格 Claudin 1 紧密连接蛋白1抗体
合格 DGAT2L6 二酰基甘油酰基转移酶2样蛋白6抗体
合格 合格 DGKA 甘油二酯激酶α/DGK-α抗体
合格 DGKB 甘油二酯激酶β/DGK-β抗体
合格 DGKD 甘油二酯激酶δ/DGK-δ抗体
合格 DGKG 甘油二酯激酶γ/DGK-γ抗体
合格 DGKI 甘油二酯激酶ι/DGK-ι抗体
合格 DGKK 甘油二酯激酶κ/DGK-κ抗体
合格 DGKZ 甘油二酯激酶ζ/DGK-ζ抗体
合格 DHI1L 11-β-羟基类固醇脱氢酶3抗体
合格 DCTN5 动力蛋白激活蛋白5抗体
合格 DHX30 ATP-依赖的RNA解旋酶30抗体
合格 DHX33 DHX33蛋白抗体